Fierce Biotech
Lilly preps for ph. 2 launch after Verve gene editor cuts cholesterol on par with PCSK9 inhibitors
Eli Lilly is laying the groundwork for a phase 2 trial of the lipid-lowering gene editor it acquired from Verve Therapeutics, with the candidate now showing strong and consistent cholesterol reduct | Eli Lilly is laying the groundwork for a phase 2 trial of the lipid-lowering gene editor it picked …
